SEC Company Response from Zosano Pharma Corp (CIK 0001587221) — Jul 12, 2021
Zosano Pharma Corp (CIK 0001587221)
Date: July 12, 2021 · CIK: 0001587221 · Accession: 0001193125-21-212946
AI Filing Summary & Sentiment
File numbers found in text: 333-257682
Show Raw Text
CORRESP 1 filename1.htm CORRESP Zosano Pharma Corporation 34790 Ardentech Court Fremont, CA 94555 July 12, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549 Re: Zosano Pharma Corporation Registration Statement on Form S-3 (Registration No. 333-257682) Ladies and Gentlemen: In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request acceleration by the U.S. Securities and Exchange Commission (the “Commission”) of the effective date of the above-referenced Registration Statement on Form S-3 (the “Registration Statement”) of Zosano Pharma Corporation (the “Company”). We respectfully request that the Registration Statement become effective as of 4:00 p.m., Washington, D.C. time, on July 14, 2021, or as soon as practicable thereafter. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Latham & Watkins LLP, by calling Richard Kim at (650) 470-4980. Thank you for your assistance in this matter. Very truly yours, Zosano Pharma Corporation By: /s/ Steven Lo Steven Lo Chief Executive Officer and President [Signature Page to Zosano Pharma Corporation Acceleration Letter]